What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

World Journal of Gastroenterology

Volumn 19, Issue 22, 2013, Pages 3375-3384

  Tarantino, Giovanni ^a,b   Finelli, Carmine ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Cancer Research Center of Mercogliano   (Italy)

^c Stella Maris Mediterraneum Foundation   (Italy)

Author keywords

Criteria; Metabolic syndrome; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Ultrasonography

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHU 508; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITAMIN D;

CARDIOVASCULAR DISEASE; ECHOGRAPHY; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STEATOSIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 84879044408     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i22.3375     Document Type: Review

References (123)

1. Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? J Gastrointestin Liver Dis 2012; 21: 205-208.
2. Tarantino G, Colao A, Capone D, Conca P, Tarantino M, Grimaldi E, Chianese D, Finelli C, Contaldo F, Scopacasa F, Savastano S. Circulating levels of cytochrome C, gamma-glu-tamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J Biol Regul Homeost Agents 2011; 25: 47-56.
3. Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, Grimaldi E, Chianese D, Gioia S, Pasanisi F, Contaldo F, Scopacasa F, Savastano S. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med 2012; 10: 50 [DOI: 10.1186/1479 -5876-10-50]
4. Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldal-amacchia G, Finelli C, Conca P, Contaldo F, Pasanisi F. Nonalcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005; 49: 289-295 [DOI: 10.1159/000087295]
5. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350 [DOI: 10.1055/s-0028-1091978]
6. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161 [DOI: 10.1159/000282080]
7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [DOI: 10.1111/j.1365-2036.2011.04724.x]
8. De Ridder RJ, Schoon EJ, Smulders JF, van Hout GC, Stock-brügger RW, Koek GH. Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery. Aliment Pharmacol Ther 2007; 26 Suppl 2: 195-201 [DOI: 10.1111/j.1365-2036.2007. 03483.x]
9. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1): CD007340.
10. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 703-716 [DOI: 10.1053/beem.2002.0225]
11. Liou I, Kowdley KV. Natural history of nonalcoholic steato-hepatitis. J Clin Gastroenterol 2006; 40 Suppl 1: S11-S16.
12. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-240 [DOI: 10.1016/j.atherosclerosis. 2006.08.021]
13. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A. Nonalcoholic steatohepatitis in type 2 diabetes mellitus. J Gas-troenterol Hepatol 2004; 19: 854-858 [DOI: 10.1111/j.1440-1746.2004.03312.x]
14. Tarantino G, Saldalamacchia G, Conca P, Arena A. Nonalcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303 [DOI: 10.1111/j.1440-1746.2007.04824.x]
15. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49: 89-96 [DOI: 10.1590/S0004-28032012000100015]
16. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007; 133: 1814-1820. [DOI: 10.1053/j.gastro. 2007.08.077]
17. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727-733.
18. Devadason CA, Scheimann AO. Overview of screening methods for fatty liver disease in children. World J Hepatol 2012; 4: 1-4 [DOI: 10.4254/wjh.v4.i1.1]
19. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011; 34: 729-749 [DOI: 10.1002/jmri.22580]
20. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [DOI: 10.1002/hep.20466]
21. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, Schick F, Häring H, Stumvoll M. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005; 37: 246-251 [DOI: 10.1055/s-2005-861411]
22. Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN, Tomlinson B. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001; 25: 1782-1788 [DOI: 10.1038/sj.ijo.0801837]
23. Sadashiv S, Paul BN, Kumar S, Chandra A, Dhananjai S, Negi MP. Over expression of resistin in adipose tissue of the obese induces insulin resistance. World J Diabetes 2012; 3: 135-141.
24. Indulekha K, Surendar J, Mohan V. High sensitivity C-reac-tive protein, tumor necrosis factor-a, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). J Diabetes Sci Technol 2011; 5: 982-988.
25. Golbidi S, Mesdaghinia A, Laher I. Exercise in the metabolic syndrome. Oxid Med Cell Longev 2012; 2012: 349710.
26. Gombet T, Longo-Mbenza B, Ellenga-Mbolla B, Ikama MS, Mokondjimobe E, Kimbally-Kaky G, Nkoua JL. Aging, female sex, migration, elevated HDL-C, and infammation are associated with prevalence of metabolic syndrome among African bank employees. Int J Gen Med 2012; 5: 495-503.
27. Malik SM, Traub ML. Defning the role of bariatric surgery in polycystic ovarian syndrome patients. World J Diabetes 2012; 3: 71-79.
28. Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011; 2011: 471584 [DOI: 10.1155/2011/471584]
29. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607 [DOI: 10.2337/diabetes.37.12.1595]
30. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
31. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide defnition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480 [DOI: 10.1111/j.1464-5491.2006.01858.x]
32. Alberti KG, Zimmet PZ. Definition, diagnosis and clas-sifcation of diabetes mellitus and its complications. Part 1: diagnosis and classifcation of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
33. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443.
34. Skilton MR, Moulin P, Sérusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome defnitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specifc differences. Atherosclerosis 2007; 190: 416-422 [DOI: 10.1016/ j.atherosclerosis.2006.02.019]
35. Ajjan R, Carter AM, Somani R, Kain K, Grant PJ. Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome. J Thromb Haemost 2007; 5: 754-760 [DOI: 10.1111/j.1538-7836.2007.02434.x]
36. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientifc issues related to defnition. Circulation 2004; 109: 433-438.
37. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010; 2: 180-193.
38. Martínez MA, Puig JG, Mora M, Aragón R, O'Dogherty P, Antón JL, Sánchez-Villares T, Rubio JM, Rosado J, Torres R, Marcos J, Pallardo LF, Banegas JR. Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid RIesgo Cardiovascular) Study. Metabolism 2008; 57: 1232-1240 [DOI: 10.1016/ j.metabol.2008.04.017]
39. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Ca-rugo S, Mancia G. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007; 25: 2463-2470 [DOI: 10.1097/HJH.0b013e3282f063d5]
40. Anagnostis P. Metabolic syndrome in the Mediterranean region: Current status. Indian J Endocrinol Metab 2012; 16: 72-80.
41. Escobedo J, Schargrodsky H, Champagne B, Silva H, Bois-sonnet CP, Vinueza R, Torres M, Hernandez R, Wilson E. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol 2009; 8: 52 [DOI: 10.1186/1475-2840-8-52]
42. Shen J, Goyal A, Sperling L. The emerging epidemic of obesity, diabetes, and the metabolic syndrome in china. Cardiol Res Pract 2012; 2012: 178675.
43. Lee J, Heng D, Ma S, Chew SK, Hughes K, Tai ES. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf) 2008; 69: 225-230 [DOI: 10.1111/j.1365-2265.2008.03174.x]
44. Park HS, Kim SM, Lee JS, Lee J, Han JH, Yoon DK, Baik SH, Choi DS, Choi KM. Prevalence and trends of metabolic syndrome in Korea: Korean National Health and Nutrition Survey 1998-2001. Diabetes Obes Metab 2007; 9: 50-58 [DOI: 10.1111/j.1463-1326.2005.00569.x]
45. Dodson MV, Mir PS, Hausman GJ, Guan LL, Du M, Jiang Z, Fernyhough ME, Bergen WG. Obesity, metabolic syndrome, and adipocytes. J Lipids 2011; 2011: 721686.
46. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond) 2009; 33: 54-66.
47. Lee K, Villena JA, Moon YS, Kim KH, Lee S, Kang C, Sul HS. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003; 111: 453-461.
48. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-139 [DOI: 10.1016/j.mce.2009.08.018]
49. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389 [DOI: 10.1016/S0092-8674(00)81359-8]
50. Frühbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 197-208 [DOI: 10.2174/1568016043356255]
51. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81-90.
52. Garg MK, Dutta MK, Mahalle N. Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome. Indian J Endocrinol Metab 2012; 16: 116-123.
53. Alikasifoglu A, Gönç N, Özön ZA, Sen Y, Kandemir N. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. J Clin Res Pediatr Endocrinol 2009; 1: 233-239.
54. Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, Wang YC, Su TP, Chou P, Chen JY. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009; 111: 1-8 [DOI: 10.1016/j.schres.2009.03.014]
55. Ahonen TM, Saltevo JT, Kautiainen HJ, Kumpusalo EA, Vanhala MJ. The association of adiponectin and low-grade infammation with the course of metabolic syndrome. Nutr Metab Cardiovasc Dis 2012; 22: 285-291 [DOI: 10.1016/j.numecd.2010.07.001]
56. Okamoto Y. Adiponectin provides cardiovascular protection in metabolic syndrome. Cardiol Res Pract 2011; 2011: 313179.
57. Brooks NL, Moore KS, Clark RD, Perfetti MT, Trent CM, Combs TP. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? Diabetes Obes Metab 2007; 9: 246-258 [DOI: 10.1111/j.1463-1326.2006.00596.x]
58. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H, Saito I. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 2010; 17: 1201-1211 [DOI: 10.5551/jat.6106]
59. Povel CM, Boer JM, Feskens EJ. Shared genetic variance between the features of the metabolic syndrome: heritability studies. Mol Genet Metab 2011; 104: 666-669 [DOI: 10.1016/j.ymgme.2011.08.035]
60. Mojiminiyi OA, Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007; 67: 215-225 [DOI: 10.1080/00365510601032532]
61. Hajianfar H, Bahonar A, Entezari MH, Askari G, Yazdani M. Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls. Int J Prev Med 2012; 3: 326-331.
62. Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pe-diatr Endocrinol 2012; 4: 76-81.
63. Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-72.
64. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-527 [DOI: 10.1002/dmrr.1201]
65. Hanley AJ, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM. Metabolic and infammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004; 53: 1773-1781 [DOI: 10.2337/diabetes.53.7.1773]
66. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Infammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700. [DOI: 10.2337/ diabetes.53.3.693]
67. Haring R, Rosvall M, Völker U, Völzke H, Kroemer H, Nauck M, Wallaschofski H. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PLoS One 2012; 7: e39461 [DOI: 10.1371/journa].
68. Sampey BP, Freemerman AJ, Zhang J, Kuan PF, Galanko JA, O'Connell TM, Ilkayeva OR, Muehlbauer MJ, Stevens RD, Newgard CB, Brauer HA, Troester MA, Makowski L. Metabolomic profling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. PLoS One 2012; 7: e38812. [DOI: 10.1371/ journal.pone.0038812]
69. Jeemon P, Prabhakaran D, Ramakrishnan L, Gupta R, Ahmed F, Thankappan K, Kartha C, Chaturvedi V, Reddy K. Association of high sensitive C-reactive protein (hsCRP) with established cardiovascular risk factors in the Indian population. Nutr Metab (Lond) 2011; 8: 19 [DOI: 10.1186/1743-7075-8-19]
70. Bouchard C, Tremblay A. Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. J Nutr 1997; 127: 943S-947S.
71. Björntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 1997; 13: 795-803. [DOI: 10.1016/ S0899-9007(97)00191-3]
72. Lemieux I, Poirier P, Bergeron J, Alméras N, Lamarche B, Cantin B, Dagenais GR, Després JP. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol 2007; 23 Suppl B: 23B-31B. [DOI: 10.1016/S0828-282X(07)71007-3]
73. Green RM. NASH--hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003; 38: 14-17 [DOI: 10.1053/jhep.2003.50325]
74. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic ste-atohepatitis. Semin Liver Dis 2001; 21: 27-41 [DOI: 10.1055/s-2001-12927]
75. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvin-en H, Svegliati-Baroni G From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330 [DOI: 10.1016/j.dld.2010.01.016]
76. Yilmaz Y, Senates E, Ayyildiz T, Colak Y, Tuncer I, Ovunc AO, Dolar E, Kalayci C. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2012; 42: 411-418 [DOI: 10.1111/j.1365-2362.2011.02597.x]
77. Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009; 58: 1706-1707 [DOI: 10.1136/gut.2009.186668]
78. Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012; 56: 241-247 [DOI: 10.1016/j.jhep.2011.05.027]
79. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304 [DOI: 10.2337/diacare.28.9.2289]
80. Saukkonen T, Jokelainen J, Timonen M, Cederberg H, Laakso M, Härkönen P, Keinänen-Kiukaanniemi S, Rajala U. Prevalence of metabolic syndrome components among the elderly using three different defnitions: a cohort study in Finland. Scand J Prim Health Care 2012; 30: 29-34 [DOI: 10.3109/02813432.2012.654192]
81. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: defnitions and controversies. BMC Med 2011; 9: 48 [DOI: 10.1186/1741-7015-9-48]
82. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132 [DOI: 10.1016/j.jacc.2010.05.034]
83. Kang HM, Kim DJ. Metabolic Syndrome versus Framing-ham Risk Score for Association of Self-Reported Coronary Heart Disease: The 2005 Korean Health and Nutrition Examination Survey. Diabetes Metab J 2012; 36: 237-244.
84. Koskinen J, Kähönen M, Viikari JS, Taittonen L, Laitinen T, Rönnemaa T, Lehtimäki T, Hutri-Kähönen N, Pietikäinen M, Jokinen E, Helenius H, Mattsson N, Raitakari OT, Juonala M. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation 2009; 120: 229-236 [DOI: 10.1161/CIRCULATIONAHA.108.845065]
85. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904 [DOI: 10.2337/dc08-0423]
86. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645 [DOI: 10.1161/CIRCU-LATIONAHA.109.192644]
87. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
88. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: 1059-1062 [DOI: 10.1016/S0140-6736(05)67402-8]
89. Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KG, Tuomilehto J, Chitson P, Shaw JE. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring) 2008; 16: 2707-2716 [DOI: 10.1038/oby.2008.412]
90. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221 [DOI: 10.1016/S0140-6736(09)60619-X]
91. Zhang Y, Sowers JR, Ren J. Pathophysiological insights into cardiovascular health in metabolic syndrome. Exp Diabetes Res 2012; 2012: 320534.
92. Kahn MB, Yuldasheva NY, Cubbon RM, Smith J, Rashid ST, Viswambharan H, Imrie H, Abbas A, Rajwani A, Aziz A, Baliga V, Sukumar P, Gage M, Kearney MT, Wheatcroft SB. Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regeneration. Diabetes 2011; 60: 1295-1303 [DOI: 10.2337/ db10-1080]
93. Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: a systematic review. Obes Rev 2011; 12: 952-967 [DOI: 10.1111/j.1467-789X.2011.00907.x]
94. Garaulet M, Madrid JA. Chronobiology, genetics and metabolic syndrome. Curr Opin Lipidol 2009; 20: 127-134 [DOI: 10.1097/MOL.0b013e3283292399]
95. Reis JP, von Mühlen D, Miller ER, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009; 124: e371-e379 [DOI: 10.1542/peds.2009-0213]
96. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden Å, Bengtsson C, Bergmark G, Bouchard C, Carlsson B, Dahlgren S, Karlsson J, Lindroos AK, Lönroth H, Narbro K, Näslund I, Olbers T, Svensson PA, Carlsson LM. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65 [DOI: 10.1001/jama.2011.1914]
97. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 2005; 112: 505-512. [DOI: 10.1161/CIRCULATIONAHA. 104.503805]
98. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, Yamada N, Sone H. Cardiorespiratory ftness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301: 2024-2035 [DOI: 10.1001/jama.2009.681]
99. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5: 295-309. [DOI: 10.1038/ nrd2005]
100. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012; 2012: 145754.
101. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996; 24: 25-29.
102. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725 [DOI: 10.1053/gast.2002.36572]
103. Zardi EM, Caturelli E. May sonography distinguish between liver fbrosis and liver steatosis? Dig Liver Dis 2007; 39: 790 [DOI: 10.1016/j.dld.2007.05.001]
104. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189: W320-W323.
105. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002; 8: 1114-1122 [DOI: 10.1053/jlts.2002.36740]
106. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, Repetto G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14: 635-637 [DOI: 10.1381/09608 9204323093408]
107. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008; 28: 386-395. [DOI: 10.1055/ s-0028-1091983]
108. Iijima H, Moriyasu F, Tsuchiya K, Suzuki S, Yoshida M, Shimizu M, Sasaki S, Nishiguchi S, Maeyama S. Decrease in accumulation of ultrasound contrast microbubbles in nonalcoholic steatohepatitis. Hepatol Res 2007; 37: 722-730 [DOI: 10.1111/j.1872-034X.2007.00130.x]
109. Iijima H, Moriyasu F, Miyahara T, Yanagisawa K. Ultrasound contrast agent, Levovist microbubbles are phagocy-tosed by Kupffer cells-In vitro and in vivo studies. Hepatol Res 2006; 35: 235-237. [DOI: 10.1016/ j.hepres.2006.04.016]
110. Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, Capone D, Pasanisi F. Young adult obese subjects with and without insulin resistance: what is the role of chronic infammation and how to weigh it non-in-vasively? J Infamm (Lond) 2009; 6: 6 [DOI: 10.1186/1476-9255-6-6]
111. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923 [DOI: 10.1053/jhep.2003.50161]
112. Tarantino G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J Gastroenterol 2007; 13: 4669-4672.
113. Tarantino G, Pizza G, Colao A, Pasanisi F, Conca P, Colic-chio P, Finelli C, Contaldo F, Di Somma C, Savastano S. Hepatic steatosis in overweight/obese females: new screening method for those at risk. World J Gastroenterol 2009; 15: 5693-5699 [DOI: 10.3748/wjg.15.5693]
114. Labruna G, Pasanisi F, Nardelli C, Tarantino G, Vitale DF, Bracale R, Finelli C, Genua MP, Contaldo F, Sacchetti L. UCP1 -3826 AG+GG genotypes, adiponectin, and leptin/ adiponectin ratio in severe obesity. J Endocrinol Invest 2009; 32: 525-529.
115. Tarantino G, Caputi A. JNKs, insulin resistance and infam-mation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011; 17: 3785-3794 [DOI: 10.3748/wjg.v17.i33.3785]
116. Tarantino G. Non-alcoholic fatty liver disease, obesity and other illnesses. Clin Invest Med 2008; 31: E290-E295.
117. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10.
118. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O'Donnell CJ, Fox CS. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepa-tology 2010; 51: 1979-1987. [DOI: 10.1002/ hep.23593]
119. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian defnitions and Asian studies. Hep-atobiliary Pancreat Dis Int 2007; 6: 572-578.
120. Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identifcation of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroen-terol 2012; 18: 1508-1516 [DOI: 10.3748/wjg. v18.i13.1508]
121. Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, Kim YJ, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Ultra-sonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol 2012; 107: 561-567 [DOI: 10.1038/ajg.2011.400]
122. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Na-kajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic fndings in nonalcoholic fatty liver disease refects the metabolic syndrome and visceral fat accumulation. Am J Gastro-enterol 2007; 102: 2708-2715. [DOI: 10.1111/ j.1572-0241.2007.01526.x]
123. Finelli C, Tarantino G. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointestin Liver Dis 2012; 21: 293-302.